Compare Merck & Co., Inc. (MRK) vs Palo Alto Networks Inc (PANW) Price & Performance

Merck & Co., Inc.Trade

Palo Alto Networks IncTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Palo Alto Networks Inc — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while Palo Alto Networks Inc trades at $342.49 (market cap $284.16B). The key difference: Merck & Co., Inc. and Palo Alto Networks Inc are close in size by market cap, and Merck & Co., Inc. pays a 2.73% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.

	MRK	PANW
Market Cap	$307.25B	$284.16B
Sector	Health	Technology
52-Week High	$129.52	$358.68
52-Week Low	$77.60	$141.67
Enterprise Value	$350.66B	$283.12B
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Palo Alto Networks Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

PANW

Palo Alto Networks to acquire Embrace, adding Real User Monitoring and Synthetics to boost app performance insights.PRNewsWire · 5 hours agoBullish Argus Research raises Palo Alto Networks price target to $425 on booming AI-driven cybersecurity demand.Danny Green · 7 hours agoBullish Cybersecurity ETFs soar as investors shift from semiconductors amid rising cyber threats and AI risks.ETF Trends · 7 hours agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.